References
1. Tarasova I.S., Chernov V.M. Factors determining the effectiveness of treatment of children with iron deficiency. Voprosy prakticheskoy pediatrii [Problems of Practical Pediatrics]. 2011; 3 (6): 49-52. (in Russian)
2. Chernov V.M.., Tarasova I.S. Federal clinical recommendations for the diagnosis and treatment of iron deficiency anemia in children. Moscow, 2013. (in Russian)
3. Stockman J.A. Anemia of prematurity: current concepts in the issue of when to transfuse. Pediatr Clin North Am. 1986; 33 (1): 111-28.
4. Zhetyshev R.A., Shabalov N.P., Ivanov D.O. Anemia of newborns. Diagnosis, prevention, treatment. Clinical recommendations. 2015. (in Russian)
5. Bert P. La Pression Barometrique. Recherches de Physiologie Ex-perimentale. Paris: Masson, 1878.
6. Erslev A.J. Blood and mountains. In: Blood, Pure and Eloquent. New York: McGraw-Hill, 1980: 257-80.
7. Pavlov A., Morshchakova E. Erythropoietin: discoveries and achievements. Meditsinskaya gazeta (Medical Newspaper). 2006; (65): 30-1. (in Russian)
8. Franklin H.B. Erythropoietin. Cold Spring Harb Perspect Med. 2013; 3: a0116119.
9. Jelkmann W. Erythropoietin after a century of research: younger than ever. Eur J Haematol. 2007; 78 (3): 183-205.
10. Lai P.H., Everett R., Wang F.F., Arakawa T., et al. Structural characterization of human erythropoietin. J Biol Chem. 1986; 261 (7): 3116-21.
11. Wang F.F., Kung C.K.H., Goldwasser E. Some chemical properties of human erythropoietin. Endocrinology. 1985; 116 (6): 2286-92.
12. Sasaki H., Bothner B., Dell A., Fukuda M. Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J Biol Chem. 1987; 262 (25): 12 059-76.
13. Davis J.M., Arakawa T., Strickland T.W., Yphantis D.A. Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells. Biochemistry 1987; 26 (9): 2633-8.
14. Merkulov V.A., Soldatov A.A., Avdeeva J.I., Alpatova N.A., et al. Recombinant erythropoietin preparations and their characteristics. Bio-preparaty (Biological Products]. 2013; (3): 4-11. (in Russian)
15. Dame C., Juul S. The switch from fetal to adult erythropoiesis. Clin Perinatol. 2000; 27: 507-26.
16. Yakovlev A.K. Studying the principles of standardization of pharmacological activity of recombinant erythropoietin preparations. Stand-artnye obraztsy (Standard Samples). 2016; (1): 8-20. (in Russian)
17. State Register of Medicines. 2017. www.grls.rosminzdrav.ru/grls.aspx. (in Russian)
18. On approval of the list of essential and essential medicines for 2016, as well as lists of medicinal products for medical use and the minimum assortment of medicines required for the provision of medical care: Decree of the Government of the Russian Federation of December 26, 2015 No. 2724-r. http://pravo.gov.ru/proxy/ips/?docbody=&nd=102387515&in%20telsearch=26.12.2015+%B9+2724-%F0. (in Russian)
19. Juul S. Erythropoietin in anemia of prematurity. J Matern Fetal Neonatal Med. 2012; 25 (5): 80-4.
20. Bechensteen A.G., Halvorsen S., Haga P., Cotes P.M., et al. Erythropoietin, protein and iron supplementation and the prevention of anaemia of prematurity; effects on serum immunoreactive Epo, growth and protein and iron metabolism. Acta Paediatr. 1996; 60: 930-5.
21. Carnielli V.P., Montini G., Da Riol R., Dallamico R., et al. Effects of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants. J Pediatr. 1992; 121: 98-102.
22. Ohls R.K., Christensen R.D. Recombinant erythropoietin compared with erythrocyte transfusion in the treatment of anemia of prematurity. J Pediatr. 1991; 119: 781-8.
23. Emmerson A. Double blind trial of recombinant human erythropoietin in preterm infants - comment. Arch Dis Child. 1993; 69: 542.
24. Obladen M., Maier R., Grauel L., et aL Recombinant human erythropoietin for prevention anaemia of prematurity: a randomized multicenter trial. Pediatr Res. 1990; 28: 287A.
25. Shannon K.M., Mentzer W.C., Abels R.I. Recombinant human erythropoietin in anaemia of prematurity: preliminary results of a double blind placebo controlled pilot study. J Pediatr. 1991; 118: 949-55.
26. Shannon K.M., Mentzer W.C., Abels R.I. Enhancement of erythro-poiesis by recombinant human erythropoietin in low birth weight infants. A pilot study. J Pediatr. 1992; 120: 586-92.
27. Ohlsson A., Aher S.M. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2012; 9: CD004863.
28. Aher S.M., Ohlsson A. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2012; 10: CD004865.
29. Aher S.M., Ohlsson A. Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2014; 4: CD004868.
30. New H.V., Berryman J., Bolton-Maggs H.B., Cantwell C., et al. Guidelines on transfusion for fetuses, neonates and older children. Br J Haematol. 2016; 175: 784-828.
31. Von Lindern JS, Lopriore E. Management and prevention of neonatal anemia: current evidence and guidelines. Expert Rev Hematol. 2014; 2: 195-202.
32. Becquet O., Guyot D., Kuo P., Pawlotsky F., et al. Respective effects of phlebotomy losses and erythropoietin treatment on the need for blood transfusion in very premature infants. BMC Pediatr. 2013; 13: 176.
33. Borisova I.P., Dmitriev A.V., Morshchakova E.F. Early anemia of prematurity: prevention and treatment. Voprosy gematologii/onkologii i immunologii v pediatrii [Problems of Hematology/Oncology and Immunology in Pediatrics]. 2004; 3 (1): 27-31. (in Russian)
34. Novikov A.B., Morshchakova E.F., Dmitriev A.B., et al. Erythropoietin in complex treatment and prevention of anemia in children under critical conditions of the neonatal period. Voprosy prakticheskoy pediatrii [Problems of Practical Pediatrics]. 2006; 1 (4): 43-7. (in Russian)
35. Pilipenko Y.N., Dmitriev A.B., Morshchakova E.F. Comparative efficacy of various doses of recombinant human erythropoietin in the prevention and treatment of anemia of prematurity. Rossiyskiy mediko-biologicheskiy vestnik im. akademika I.P. Pavlova [Russian Medical and Biological Bulletin of I.P. Pavlov]. 2008; (4): 97-103. (in Russian)
36. Demikhov V.G., Dmitriev A.V., Shoker O.A., Demikhova E.V. Early anemia of premature newborns: optimization of therapeutic strategies. Rossiyskiy zhurnal detskoy gematologii i onkologii [Russian Journal of Pediatric Hematology and Oncology]. 2015; 1: 81-7. (in Russian)
37. Pilipenko Yu.N. The use of recombinant human erythropoietin in the prevention of anemia in premature newborns with very low and extremely low birth weight: Autoabstract of Diss. Ryazan', 2009: 28 p. (in Russian)
38. Sharafutdinova D.R., Balashova E.N., Pavlovich S.V., Ionov O.V., et al. Efficiency of prevention and treatment of anaemia of prematurity in extremely and very low birth weight infants. Voprosy gematologii/onkologii i immunologii v pediatrii [Problems of Hematology/Oncology and Immunology in Pediatrics]. 2017; 16 (4): 13-20. (in Russian)
39. Sinclair A.M. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood. 2010; 1: 4264-72.
40. D'Andrea A.D., Zon L.I. Erythropoietin receptor. Subunit structure and activation. J Clin Invest. 1990; 86 (3): 681-7.
41. Sawyer S.T., Krantz S.B., Sawada K. Receptors for erythropoietin in mouse and human erythroid cells and placenta. Blood. 1989; 74 (1): 103-9.
42. Anagnostou A. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA. 1991; 91 (9): 57-65.
43. Akimoto T. Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway. Kidney Int. 2000; 58 (1): 269-82.
44. Ammarguellat F., Llovera M., Kelly P.A., Goffin V. Low doses of EPO activate MAP kinases but not JAK2-STAT5 in rat vascular smooth muscle cells. Biochem Biophys Res Commun. 2001; 284 (4): 1031-8.
45. Heeschen C. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood. 2003; 102 (4): 1340-46.
46. Bahlmann F.H. Erythropoietin regulates endothelial progenitor cells. Blood. 2004; 103 (3): 921-6.
47. Akimoto T. Involvement of erythropoietin-induced cytosolic free calcium mobilization in activation of mitogen-activated protein kinase and DNA synthesis in vascular smooth muscle cells. J Hypertens. 2001; 19 (2): 193-202.
48. Wojchowski D.M., Gregory R.C., Miller C.P., Pandit A.K., et al. Signal transduction in the erythropoietin receptor system. Exp Cell Res. 1999; 253 (1): 143-56.
49. Eefting F. Role of apoptosis in reperfusion injury. Cardiovasc Res. 2004; 61 (3): 414-26.
50. Cai Y.J., Song Y.Y., Huang Z.J., et al. Effects of recombinant human erythropoietin on neurointelligence development in very low birth weight infants. Zhongguo Dang Dai Er Ke Za Zhi. 2013; 15 (12): 1064-7.
51. Juan S., Huiqing S., Falin X., Wenqing K., et al. Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Ann Neurol. 2016; 80 (1): 24-34.
52. Wu Y.W., Bauer L.A., Ballard R.A., et al. Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics. Pediatrics. 2012; 130: 683-91.
53. Rayjada N., Barton L., Chan L.S., et al. Decrease in incidence of bronchopulmonary dysplasia with erythropoietin administration in preterm infants: a retrospective study. Neonatology. 2012; 102: 287-92.
54. Ananthan A., Balasubramanian H., Rao S., Patole S. Clinical outcomes related to the gastrointestinal trophic effects of erythropoietin in preterm neonates: a systematic review and meta-analysis. Adv Nutr. 2018; 9 (3): 238-46.
55. Leuchter R.H., Gui L., Poncet A., et al. Association between early administration of high-dose erythropoietin in preterm infants: EPO in Very Preterm Infants and brain MRI abnormality at term-equivalent age. JAMA. 2014; 312: 817-24.
56. McAdams R.M., McPherson R.J., Mayock D.E., Juul S.E. Outcomes of extremely low birth weight infants given early high-dose erythropoietin. J Perinatol. 2013; 33: 226-30.
57. O'Gorman R.L., Bucher H.U., Held U., et al. Tract-based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain. 2015; 138 (2): 388-97.
58. Fauchere J.C., Koller B.M., Tschopp A., et al. Safety of early high dose recombinant erythropoietin for neuroprotection in very preterm infants. J Pediatr. 2015; 167: 52-7.
59. OhLs R.K., et aL. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics. 2014; 133 (6): 1023-30.
60. Luciano R., FracchioLLa A., Ricci D., Cota F., et aL. Are high cumulative doses of erythropoietin neuroprotective in preterm infants? A two year foLLow-up report. ItaL J Pediatr. 2015; 41: 64-8.
61. Pathipati P., Ferriero M.D. The differential effects of erythropoietin exposure to oxidative stress on microglia and astrocytes in vitro. Dev. Neurosci. 2017; 39 (1-4): 310-22.
62. Kandasamy Y., Kumar P., Hartley L. The effect of erythropoietin on the severity of retinopathy of prematurity. Eye (Lond). 2014; 28 (7): 814-8.
63. Manzoni P., Memo L., Mostert M., GaLLo E., Guardione R., et aL. Use of erythropoietin is associated with threshoLd retinopathy of prematurity (ROP) in preterm ELBW neonates: a retrospective, cohort study from two Large tertiary NICUs in ItaLy. EarLy Hum. Dev. 2014; 90 (2): 29-33.
64. Chou H-H, et aL. EarLy erythropoietin administration does not increase the risk of retinopathy in preterm infants. Pediatr NeonatoL. 2016; 4: 1-9.
65. KetLinsky C.A., Simbirtsev A.S. Cytokines. Saint Petersburg: Fo-Liant, 2008: 552 p. (in Russian)
66. Henry D.H., DahL N.V., Auerbach M.A. Thrombocytosis and venous thromboemboLism in cancer patients with chemotherapy induced anemia may be reLated to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. Am J HematoL. 2012; 87 (3): 308-10.
67. Casati s. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodiaLysis. Br Med J. 1987; 295: 1017-20.
68. ZaffaneLLo M. Recombinant human erythropoietin might induce strawberry haemangiomas in very-Low-birth-weight preterm infants. Pediatrics. 2003; 2: 22-31.
69. HoLm M., Skranes J., Dammann O., Fichorova R.N., et aL. Systemic endogenous erythropoietin and associated disorders in extremeLy preterm newborns. Arch Dis Child FetaL NeonataL Ed. 2016; 101 (5): 458-63.
70. PoLgLase G.R., Barton S.K., MeLviLLe J.M., et aL. ProphyLactic erythropoietin exacerbates ventiLation-induced Lung inflammation and injury in preterm Lambs. J PhysioL (Lond). 2014; 592 (9): 1993-2002.
71. Wu W.T., Hu T.M., Lin N.T., et aL. Low-dose erythropoietin aggravates endotoxin-induced organ damage in conscious rats. Cytokine. 2010; 49: 155-62.
72. Korzeniewski S.J., ALLred E.J., Logan W., Fichorova R.N., et aL. ELevated endogenous erythropoietin concentrations are associated with increased risk of brain damage in extremeLy preterm neonates. PLoS One. 2015; 10 (3): 83-115.